Lantheus (LNTH) Competitors $89.29 -2.65 (-2.88%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends LNTH vs. TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, CTLT, and PCVXShould you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Lantheus vs. Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Teva Pharmaceutical Industries (NYSE:TEVA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Does the media refer more to TEVA or LNTH? In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Lantheus. MarketBeat recorded 26 mentions for Teva Pharmaceutical Industries and 13 mentions for Lantheus. Lantheus' average media sentiment score of 1.00 beat Teva Pharmaceutical Industries' score of 0.61 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in TEVA or LNTH? Teva Pharmaceutical Industries received 988 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.81% of users gave Teva Pharmaceutical Industries an outperform vote while only 65.83% of users gave Lantheus an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes132767.81% Underperform Votes63032.19% LantheusOutperform Votes33965.83% Underperform Votes17634.17% Do analysts recommend TEVA or LNTH? Teva Pharmaceutical Industries presently has a consensus price target of $20.88, indicating a potential downside of 5.50%. Lantheus has a consensus price target of $131.86, indicating a potential upside of 47.67%. Given Lantheus' stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Lantheus 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in TEVA or LNTH? 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 1.5% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, TEVA or LNTH? Teva Pharmaceutical Industries has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Is TEVA or LNTH more profitable? Lantheus has a net margin of 28.57% compared to Teva Pharmaceutical Industries' net margin of -5.73%. Lantheus' return on equity of 44.29% beat Teva Pharmaceutical Industries' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-5.73% 42.92% 7.25% Lantheus 28.57%44.29%23.52% Which has preferable earnings and valuation, TEVA or LNTH? Lantheus has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.77B1.49-$559M-$0.85-25.99Lantheus$1.50B4.15$326.66M$6.0114.86 SummaryLantheus beats Teva Pharmaceutical Industries on 13 of the 18 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Lantheus News Delivered to You Automatically Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNTH vs. The Competition Export to ExcelMetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.21B$2.51B$5.02B$9.08BDividend YieldN/A0.73%4.87%4.18%P/E Ratio14.866.07135.2017.17Price / Sales4.1575.031,120.31115.67Price / Cash13.5515.0540.5837.88Price / Book7.503.284.754.78Net Income$326.66M$29.98M$118.50M$225.60M7 Day Performance-4.01%-1.24%-1.83%-1.26%1 Month Performance3.29%10.59%12.27%4.37%1 Year Performance53.39%-22.23%31.72%18.73% Lantheus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNTHLantheus4.3768 of 5 stars$89.29-2.9%$131.86+47.7%+53.4%$6.21B$1.50B14.86834Analyst ForecastHigh Trading VolumeTEVATeva Pharmaceutical Industries1.8805 of 5 stars$16.77+1.6%$19.67+17.3%+112.2%$19.00B$16.77B-19.7937,851Analyst DowngradeOptions VolumeNews CoverageBGNEBeiGene2.6115 of 5 stars$176.95-1.3%$253.69+43.4%+0.7%$17.24B$2.46B-21.7710,600MRNAModerna4.2664 of 5 stars$41.63-0.5%$79.50+91.0%-54.3%$16.02B$5.06B-7.195,600Analyst DowngradeVTRSViatris2.0581 of 5 stars$12.74+0.9%$13.67+7.3%+19.8%$15.21B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2652 of 5 stars$18.21+2.1%$33.33+83.0%+636.9%$13.43B$700,000.00-63.68105News CoverageGMABGenmab A/S4.2355 of 5 stars$20.21+0.2%$45.20+123.7%-33.5%$13.37B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.8457 of 5 stars$14.76+2.1%$17.00+15.2%+15.8%$12.32B$299.87B22.9527,048Analyst DowngradeNews CoverageSRPTSarepta Therapeutics4.8116 of 5 stars$127.00+2.7%$178.71+40.7%+31.8%$12.13B$1.64B98.971,314Analyst ForecastCTLTCatalent2.7788 of 5 stars$63.47+0.6%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.6049 of 5 stars$90.74+3.4%$147.50+62.6%+45.4%$11.31BN/A-19.07160Analyst ForecastInsider Trade Related Companies and Tools Related Companies TEVA Competitors BGNE Competitors MRNA Competitors VTRS Competitors SMMT Competitors GMAB Competitors RDY Competitors SRPT Competitors CTLT Competitors PCVX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LNTH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LNTH Stock Alerts